1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Biosimilars Business Review Q4 2015

Biosimilars Business Review Q4 2015

  • December 2015
  • -
  • Espicom Business Intelligence
  • -
  • 40 pages

Industry Trend Analysis - US Biosimilar Market Set To Take Off In 2016
Industry Trend Analysis - FDA Must Increase Pace Of Biosimilar Programme
Industry Trend Analysis - Etanercept Filing Highlights Sandoz' Early Lead In US Biosimilar Market
Industry Trend Analysis - Kadcyla Compulsory Licence Request Will Increase Pricing Pressure For Roche
Industry Trend Analysis - Balancing Protection And Access Essential For EU Biosimilar Market To Succeed
Industry Trend Analysis - Pivotal Trial Keeps Momenta/Baxalta Adalimumab On Track For 2018 Launch
Industry Brief - Cinfa Biotech Initiates Biosimilar Strategy
Industry Trend Analysis - California Biosimilar Legislation Is Encouraging But Remains Premature
Industry Trend Analysis - Irish Guidance Highlights Common Themes In Emerging Biosimilar Market
Industry Trend Analysis - US To Become Sandoz' Dominant Market
Industry Trend Analysis - BioMab Divestment Will Aid Cipla's Biosimilar Ambitions
Industry Brief - ProBioGen and Bio Farma Enter Trastuzumab Agreement
Industry Trend Analysis - FTC's Outlook Impedes FDA Biosimilar Naming Plans
Industry Brief - mAbxience Opens European Biosimilars Facility
Industry Trend Analysis - TPP Agreement Will Face National Implementation Battles
Industry Brief - BI Completes Biosimilar Adalimumab Phase III Enrolment
Industry Trend Analysis - CHS-0214 On Target For European Filing In Late 2016
Industry Brief - Sandoz' Third Biosimilar Application Accepted By The FDA
Industry Trend Analysis - Amgen A Leader In Race For Biosimilar RA Market
Industry Trend Analysis - Samsung Bioepis Set To Win EU Biosimilar Etanercept First-To-Market Race
Industry Trend Analysis - US Filing Underlines Amgen's Biosimilar Market Leader Ambitions
Industry Brief - Merck To Enter Canadian Biosimilar Market
Industry Brief - Samsung Bioepis' Renflexis Biosimilar Approved In South Korea
Industry Brief - Amgen Submits Biosimilar Adalimumab MAA To EMA
Industry Brief - EMA Accepts Sandoz' Etanercept Submission
Industry Brief - EMA Commences Evaluation Of Gedeon Richter's Pegfilgrastim

Table Of Contents

Biosimilars Business Review Q4 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.